Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Conti

Showing results (171-180 of 180) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 180 results.
Journal of Cellular Physiology|May 26, 2017
GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancerLaura Pizzuti, Domenico Sergi, Chiara Mandoj, et al.
Journal of Cancer|March 10, 2016
Metabolic Determinants and Anthropometric Indicators Impact Clinical-pathological Features in Epithelial Ovarian Cancer PatientsPatrizia Vici, Laura Pizzuti, Luigi Di Lauro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2021
Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single InstitutionVincenzo Di Noia, Fulvia Pimpinelli, Davide Renna, et al.
Frontiers in Oncology|August 8, 2020
Thymic Epithelial Tumors as a Model of Networking: Development of a Synergistic Strategy for Clinical and Translational Research PurposesEnrico Melis, Enzo Gallo, Simona di Martino, et al.
Leukemia|September 21, 2021
Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin's lymphomasFrancesco Marchesi, Fulvia Pimpinelli, Diana Giannarelli, et al.
Vaccines|October 26, 2021
Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care WorkersFlaminia Campo, Aldo Venuti, Fulvia Pimpinelli, et al.
Vaccines|July 2, 2021
Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMIRaul Pellini, Aldo Venuti, Fulvia Pimpinelli, et al.
Eclinicalmedicine|June 10, 2021
Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccineRaul Pellini, Aldo Venuti, Fulvia Pimpinelli, et al.
Frontiers in Immunology|February 12, 2024
Dynamics of humoral and cellular response to three doses of anti-SARS-CoV-2 BNT162b2 vaccine in patients with hematological malignancies and older subjectsValentina Laquintana, Carla Mottini, Francesco Marchesi, et al.
Nature Communications|May 11, 2023
p140Cap inhibits β-Catenin in the breast cancer stem cell compartment instructing a protective anti-tumor immune responseVincenzo Salemme, Mauro Vedelago, Alessandro Sarcinella, et al.
Pageof 18

Showing results (171-180 of 180) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 180 results.
Journal of Cellular Physiology|May 26, 2017
GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancerLaura Pizzuti, Domenico Sergi, Chiara Mandoj, et al.
Journal of Cancer|March 10, 2016
Metabolic Determinants and Anthropometric Indicators Impact Clinical-pathological Features in Epithelial Ovarian Cancer PatientsPatrizia Vici, Laura Pizzuti, Luigi Di Lauro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2021
Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single InstitutionVincenzo Di Noia, Fulvia Pimpinelli, Davide Renna, et al.
Frontiers in Oncology|August 8, 2020
Thymic Epithelial Tumors as a Model of Networking: Development of a Synergistic Strategy for Clinical and Translational Research PurposesEnrico Melis, Enzo Gallo, Simona di Martino, et al.
Leukemia|September 21, 2021
Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin's lymphomasFrancesco Marchesi, Fulvia Pimpinelli, Diana Giannarelli, et al.
Vaccines|October 26, 2021
Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care WorkersFlaminia Campo, Aldo Venuti, Fulvia Pimpinelli, et al.
Vaccines|July 2, 2021
Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMIRaul Pellini, Aldo Venuti, Fulvia Pimpinelli, et al.
Eclinicalmedicine|June 10, 2021
Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccineRaul Pellini, Aldo Venuti, Fulvia Pimpinelli, et al.
Frontiers in Immunology|February 12, 2024
Dynamics of humoral and cellular response to three doses of anti-SARS-CoV-2 BNT162b2 vaccine in patients with hematological malignancies and older subjectsValentina Laquintana, Carla Mottini, Francesco Marchesi, et al.
Nature Communications|May 11, 2023
p140Cap inhibits β-Catenin in the breast cancer stem cell compartment instructing a protective anti-tumor immune responseVincenzo Salemme, Mauro Vedelago, Alessandro Sarcinella, et al.
Pageof 18